Evidence map›Paper›PMID 36286470›Full record

ArticleMarine drugs2022

Manzamine-A Alters In Vitro Calvarial Osteoblast Function.

Samantha Hardy, Yeun-Mun Choo, Mark Hamann, James Cray

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Manzamine-A AltersJournal of natural products · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Samantha HardyDepartment of Biomedical Education and Anatomy, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Yeun-Mun ChooChemistry Department, Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia.
Mark HamannDepartments of Drug Discovery and Biomedical Sciences and Public Health, Colleges of Pharmacy and Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
James CrayDepartment of Biomedical Education and Anatomy, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University · USAmerican Association of Colleges of Pharmacy · USUniversity of Malaya · MY

Funding

Synthesis and Optimization of the Aleutianamine Class of AlkaloidsR01GM145845 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAMANN, MARK T, TIUS, MARCUS ANTONIUS · 2022 to 2025
$2.4M
NIGMS NIH HHS R01 GM145845
6 · The paper itself

Abstract

Manzamine-A is a marine-derived alkaloid which has anti-viral and anti-proliferative properties and is currently being investigated for its efficacy in the treatment of certain viruses (malaria, herpes, HIV-1) and cancers (breast, cervical, colorectal). Manzamine-A has been found to exert effects via modulation of SIX1 gene expression, a gene critical to craniofacial development via the WNT, NOTCH, and PI3K/AKT pathways. To date little work has focused on Manzamine-A and how its use may affect bone. We hypothesize that Manzamine-A, through SIX1, alters bone cell activity. Here, we assessed the effects of Manzamine-A on cells that are responsible for the generation of bone, pre-osteoblasts and osteoblasts. PCR, qrtPCR, MTS cell viability, Caspase 3/7, and functional assays were used to test the effects of Manzamine-A on these cells. Our data suggests Six1 is highly expressed in osteoblasts and their progenitors. Further, osteoblast progenitors and osteoblasts exhibit great sensitivity to Manzamine-A treatment exhibited by a significant decrease in cell viability, increase in cellular apoptosis, and decrease in alkaline phosphatase activity. In silico binding experiment showed that manzamine A potential as an inhibitor of cell proliferation and survival proteins, i.e., Iκb, JAK2, AKT, PKC, FAK, and Bcl-2. Overall, our data suggests Manzamine-A may have great effects on bone health overall and may disrupt skeletal development, homeostasis, and repair.

Indexed as

Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAlkaline PhosphataseCarbazolesCaspase 3Cell DifferentiationOsteoblastsOsteogenesisProto-Oncogene Proteins c-bcl-2Alkaline PhosphataseCarbazolesCaspase 3manzamine APhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2bonemanzamineosteoblastosteogenesissix1

Identifiers

PMID36286470
PMCPMC9604769
OpenAlexW4306773189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.